EVP, Research & Investments · Royalty Pharma plc · Royalty Pharma plc — LP interests in RPI US Partners 2019, LP
Side
C
Value
—
Shares
16.0K
Price
—
Executed
Nov 7, 2025
Disclosed
Nov 7, 2025
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Nov 7 executedNov 7, 2025 disclosed
RPRX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Derivative conversion — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 6.9% of prior position
Filing timing0 / 15
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Royalty Pharma plc — LP interests in RPI US Partners 2019, LP
Ticker
RPRX
Shares
16.0K
Price per share
$0
Execution date (reported)
Nov 7, 2025
Owned after transaction
247.4K shares
Days from execution to publication
0
What this establishes
Urist Marshall filed this Form 4 reporting a derivative conversion of RPRX on Nov 7, 2025. It became public on Nov 7, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
EVP, Research & Investments
Urist Marshallcik:0001838139
Issuer
Royalty Pharma plccik:0001802768
Revision history · 0
No field has changed since this record was first ingested.
